Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4703391 | 0.90 | ADRA2A (0.42) | ELANEADRA2ANISCHCYP2C19KMT2A | |
| SCHEMBL4700275 | 0.90 | ELANE (0.46) | ELANEADRA2ANISCHCYP2C19KMT2A | |
| SCHEMBL4701273 | 0.85 | ELANE (0.42) | ELANEADRA2ANISCHCYP2C19KMT2A | |
| SCHEMBL14564783 | 0.85 | ELANE (0.42) | ELANEADRA2ANISCHCYP2C19KMT2A | |
| SCHEMBL4698661 | 0.85 | ELANE (0.43) | ELANEADRA2ANISCHCYP2C19KMT2A | |
| SCHEMBL4702789 | 0.83 | CMA1 (0.49) | ELANEADRA2ANISCHCYP2C19KMT2A | |
| SCHEMBL4697212 | 0.81 | KMT2A (0.46) | ELANEADRA2ANISCHCYP2C19KMT2A | |
| SCHEMBL4701920 | 0.81 | TDP1 (0.56) | ADRA2ANISCHCYP2C19KMT2AMEN1 | |
| SCHEMBL4700020 | 0.81 | ELANE (0.47) | ELANEADRA2ANISCHCYP2C19KMT2A | |
| SCHEMBL14564776 | 0.81 | ELANE (0.47) | ELANEADRA2ANISCHCYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1440059-B1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070054950-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | PFIZER INC. | 2007-03-08 | — | — | US | disclosed |
| US-7049335-B2 | 3-azabicyclo[3.1.0]hexane derivatives | PFIZER INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-20050171178-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| US-20030087898-A1 | 3-azabicyclo[3.1.0]hexane derivatives | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087898-A1 | 3-azabicyclo[3.1.0]hexane derivatives | OPRD1, OPRM1, OPRK1 | ELANE 1990/4885ADRA2A 163/4885NISCH 2548/4885 |
| US-20050171178-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | OPRD1, OPRM1, OPRK1 | ELANE 1589/4885ADRA2A 206/4885NISCH 2256/4885 |
| US-20070054950-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | OPRD1, OPRM1, OPRK1 | ELANE 1589/4885ADRA2A 219/4885NISCH 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.